For treatment of post-polycythaemia vera myelofibrosis - EMA/OD/139/14* For treatment of primary myelofibrosis - EMA/OD/140/14* For treatment of pyridoxamine 5'-phosphate oxidase deficiency - EMA/OD/104/14* For treatment of refractory and/or relapsed Richter's transformation - EMA/OD...
STOCKHOLM, Oct. 5, 2023 /PRNewswire/ --Calliditas Therapeutics AB(Nasdaq: CALT) (Nasdaq Stockholm: CALTX)(“Calliditas”) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) ...
CHMP, Committee on Medicinal Products for Human Use COMP, Committee on Orphan Medicinal Products CVMP, Committee on Medicinal Products for Veterinary Use HCMP, Committee on Herbal Medicinal Products PDCO, Pediatric Committee on the Evaluation of Medicinal Products PRAC, Pharmacovigilance Risk Assessment Co...
European Medicines Agency. Committee for Orphan Medicinal Products. Public summary of positive opinion for orphan designation of bosentan. Document reference EMEA/COMP/270/03 Rev.1. May 2007The Committee for Orphan Medicinal Products (COMP). 2007; Available at: http://www.emea.europa.eu/htms/...
The Committee for Orphan Medicinal Products (COMP), the European Medicines Agency committee responsible for evaluation of applications for orphan designation (OD), received an increasing flow of applications in the field of gene therapies over the last years. Here, the ...
Circus, WestferryWharf, CanaryEMEA ‐ Report on the first 3‐year mandate of the Committee for Orphan Medicinal Products (COMP) (April 2000‐April 2003).
NA;Inpharma weekly
The Committee for Orphan Medicinal Products of the European Medicines Agency has granted PTC 124 [PTC Therapeutics] orphan drug statusNA;Inpharma weekly
The Committee for Orphan Medicinal Products of the EMEA has granted orphan drug status to maribavir
2003/296/EC: Commission Decision of 28 April 2003 appointing members of the Committee for Orphan Medicinal Products (Text with EEA relevance)doi:32003D02962003/296/EC:2003年4月28日委员会决定任命孤儿药品委员会成员(与欧洲经济区相关的文本)